Veranova to expand ADCs and high potency site
Veranova has initiated a “significant” expansion of its ADC and highly potent compound development and manufacturing capabilities at Devens, Massachusetts, at a cost of about $30 million. The company said that this will address growing demand for strong US-based capacity for ADCs and other potent small molecules.
The expansion will include a new high potent process development laboratory and two new cGMP suites designed to handle potent compounds with OELs of <0.01 µg/m3. These will feature dedicated air handling systems, airlocks for clean-in-place operations, isolator technology and processing capabilities, including synthesis reactors, chromatography, thin film evaporators and lyophilisation.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
